This new combo drug shows the possibility to repair the heart and fractured bones and also autoimmune diseases like rheumatoid arthritis, by encouraging the bone marrow to release some extra support of adult stem cells into the main blood stream.
Rankin who lead the study is hopeful that the study in mice open up the possibility to call up extra number of any types, as per the requirement of body.
They treated healthy mice with one of two proteins that occur naturally in bone marrow called VEGF and G-CSF growth factor. Following this treatment the mice received Genzyme’s stem-cell transplantation drug Mozobil.
While well known about the result of G-CSF in combination with Mozobil, which mobilizes stem cells that used in bone marrow transplantation known as haematopoietic stem cells, which give rise to blood cells. Rankin and colleagues wanted to see if VEGF growth factor could stimulate other types of stem cells involved in building heart and bone tissue and blood vessels.
The team, which reported the findings in the journal Cell Stem Cell, The result was in their favour, mice given VEGF and Mozobil released around 100 times as many endothelial and mesenchymal stem cells into the bloodstream compared to mice that had no treatment.
The team, reported their findings in the journal Cell Stem Cell.
They are now looking forward to investigate whether releasing repair stem cells into the blood really does accelerate the rate and degree of tissue regeneration in mice that have had a heart attack.
Depending on the outcome of their work, they hope to conduct clinical trials of the new drug combinations in humans within the next ten years.